Becton Dickinson/$BDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Becton Dickinson
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Ticker
$BDX
Sector
Primary listing
NYSE
Employees
70,000
Headquarters
Website
Becton Dickinson Metrics
BasicAdvanced
$52B
31.21
$5.82
0.29
$4.16
2.29%
Price and volume
Market cap
$52B
Beta
0.29
52-week high
$251.99
52-week low
$162.29
Average daily volume
2.1M
Dividend rate
$4.16
Financial strength
Current ratio
1.113
Quick ratio
0.438
Long term debt to equity
69.401
Total debt to equity
75.545
Dividend payout ratio (TTM)
71.28%
Interest coverage (TTM)
5.18%
Profitability
EBITDA (TTM)
5,635
Gross margin (TTM)
45.89%
Net profit margin (TTM)
7.68%
Operating margin (TTM)
14.53%
Effective tax rate (TTM)
10.79%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
3.52%
Return on equity (TTM)
6.54%
Valuation
Price to earnings (TTM)
31.21
Price to revenue (TTM)
2.392
Price to book
2.05
Price to tangible book (TTM)
-4.9
Price to free cash flow (TTM)
19.569
Free cash flow yield (TTM)
5.11%
Free cash flow per share (TTM)
9.282
Dividend yield (TTM)
2.29%
Forward dividend yield
2.29%
Growth
Revenue change (TTM)
8.24%
Earnings per share change (TTM)
-0.68%
3-year revenue growth (CAGR)
4.99%
10-year revenue growth (CAGR)
7.82%
3-year earnings per share growth (CAGR)
-0.35%
10-year earnings per share growth (CAGR)
5.68%
3-year dividend per share growth (CAGR)
6.13%
10-year dividend per share growth (CAGR)
5.65%
What the Analysts think about Becton Dickinson
Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.
Bulls say / Bears say
Sales from the BD Medical unit grew 12.7% to $2.76 billion in Q2 (ended March 31), surpassing the $2.75 billion estimate and showing strong demand for its drug-delivery devices (Reuters).
Management raised the bottom end of its fiscal 2025 revenue outlook to $21.8 billion from $21.7 billion, citing expected benefits from a weaker U.S. dollar, reaffirming its full-year growth expectations (Reuters).
BD agreed to spin off its Biosciences & Diagnostic Solutions division through a $17.5 billion Reverse Morris Trust merger with Waters, a tax-efficient deal expected to generate $345 million in annual cost synergies and create a combined entity with $6.5 billion in 2025 revenue (Reuters).
Reported Q2 revenue of $5.27 billion fell short of the $5.35 billion consensus, indicating weakness in core medical and diagnostic product sales (Reuters).
The company expects a $0.25-per-share headwind to 2025 adjusted EPS from U.S. tariffs, leading it to lower its full-year profit forecast to $14.06–$14.34 from $14.30–$14.60 and signaling margin pressure (Reuters).
Cuts in global research funding, especially in U.S. government grants, have hurt sales of research instruments, causing a 0.9% decline in the bioscience unit and triggering the largest single-day share drop in 26 years (MarketWatch).
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
Becton Dickinson Financial Performance
Revenues and expenses
Becton Dickinson Earnings Performance
Company profitability
Becton Dickinson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Becton Dickinson stock?
Becton Dickinson (BDX) has a market cap of $52B as of November 12, 2025.
What is the P/E ratio for Becton Dickinson stock?
The price to earnings (P/E) ratio for Becton Dickinson (BDX) stock is 31.21 as of November 12, 2025.
Does Becton Dickinson stock pay dividends?
Yes, the Becton Dickinson (BDX) stock pays dividends to shareholders. As of November 12, 2025, the dividend rate is $4.16 and the yield is 2.29%. Becton Dickinson has a payout ratio of 71.28% on a trailing twelve-month basis.
When is the next Becton Dickinson dividend payment date?
The next Becton Dickinson (BDX) dividend payment is scheduled for December 31, 2025.
What is the beta indicator for Becton Dickinson?
Becton Dickinson (BDX) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.